Home / Transcripts / Nanoform Finland Oyj (NANOFH) · August 20, 2026

Nanoform Finland Oyj (NANOFH) Earnings Call Transcript

August 20, 2026

Nasdaq Helsinki FI Health Care Life Sciences Tools and Services earnings 59 min

Earnings Call Speaker Segments

Operator operator
#1

Thanks for joining this conference call. At the start, everyone will be in listen-only mode. When we get to the question-and-answer session, you can ask a question by pressing star five on your phone's keypad. I'll now pass things over to the speakers. Go ahead.

Henri von Haartman executive
#2

Thank you, operator. Hello everyone, and a very warm welcome to the presentation of Nanoform's second quarter 2026 report. I'm Henri von Haartman, Director of Investor Relations. With us today are our CEO, Edward Hæggström; CFO, Albert Hæggström; Chief Commercial Officer, Christian Jones; and Chief Development Officer, Peter Hänninen, who will all present. This presentation is webcasted through Investor Wall, and you can also call in and listen by phone. The presentation slides are shown throughout the webcast, and they can be found on our web page in the investor section. After the presentation, we will hold a Q&A, and it's possible to ask questions by calling in. We will today start with a short introduction, then key business highlights, then financials, then commercial, and we conclude with our product kernels and the biologics market. With these words, our CEO and founder, Edward Hæggström, please go ahead.

Edward Hæggström executive
#3

Thank you, Henri, and welcome from me as well. What we'll cover today is the UK response, our lower cash burn, and the bio-GMP CDMO negotiations. Let's move to the next slide, please. I believe it's worth stating that we are carrying out the strategy that was laid out at the Capital Markets Day in December 2025. That is essentially the framework. We provide both services and development across small molecules, biologics, and formulation, and a strong AI platform backs us up. Our client base spans global pharma, mid-sized and specialty pharma, along with biotechs. We have 2 technologies, and at present those are small molecules and biologics. Revenue reaches Nanoform through service fees, developmental and commercial milestones, commercial GMP supply, and then exclusivity fees, royalties, and profit shares. The mid-term targets for 2030 were set out at the Capital Markets Day: 3 Nanoformed medicines launched by 2030, income growth greater than 50% CAGR, and an EBITDA margin above 30% by 2030. Next, please. We have 4 business highlights here. We have now received positive feedback from the scientific advice meeting in the UK. That means we remain on track to file our first marketing authorization application for nanoenzalutamide.

Edward Hæggström executive
#4

We anticipate that taking place in 2026. Our cash flow has improved markedly, which indicates that the goal of keeping cash burn under 10 million remains on schedule. Beyond that, we've worked hard to elevate our standing on the biologics side to GMP. That means we are now in negotiations with reputable CDMOs about precisely how to accomplish this. Peter will go into more detail. And the years ahead are really about getting ready to launch Nanoform products: first in small molecules, and afterward in large molecules. We'll do this alongside our partners, and it will have an impact globally. Next, please. I'll hand things over to Albert.

Albert Hæggström executive
#5

Thanks, Edward. Now, moving on to some figures, you can see here the count of projects we signed. During Q2, we signed 3 GMPs along with 3 non-GMPs — the first occasion on which both categories were equal in number. Over on the right, you'll notice that in line with our strategy, we've managed to raise the share of GMP projects, and the ones signed tie back to our kernels on the small molecule side. Moving to the next page, on income, you can see that income grew during the first half. What matters to remember here is that for the deal we struck with a biopharmaceutical company listed on Nasdaq, only a small share of it lands in P&L during Q2, whereas the entire amount we received, $1 million, went into cash flow — which explains why cash flow looks slightly stronger than P&L. On the right side, we can also see that gross margin once again came in above 90%, which is, naturally, the level we target. Turning to operating expenses, these declined 33% in the first half, and that naturally stems from our emphasis on trimming the cost structure.

Albert Hæggström executive
#6

You can also see that because we managed to get the factory built — and once it's up, we need fewer people and lower costs. Building a factory with all the systems and the various functions is quite expensive, and now the impact is starting to show from having essentially completed the factory on the small molecule side. The trend so far this year has been very good. That, of course, feeds straight into EBITDA, which you can see on the right-hand side. As I said, cash flow was even better than the P&L, and we actually burned only 1.5 million in the second quarter, which means the half-year cash burn this year came to 5 million, and that means we're on track to hit our full-year cash burn target, which is below 10 million in cash burn. The 1.5 million cash burn in the second quarter also meant our cash stood at 19 million at the end of the quarter, versus 20.5 million at the end of the first quarter. I think we've done a really good job of reducing the cash burn, and we believe the cash pile is sufficient until we reach cash flow positive.

Albert Hæggström executive
#7

So here are the near-term business targets for this year: cash burn under 10 million — we're on track for that; the first marketing authorization application for a Nanoformed medicine has been submitted, and following the positive feedback from the scientific advice in the UK, we're on track on that one too; more non-GMP and GMP projects signed in '26 — we're on track there as well; and we're working hard to hit the fourth near-term business target too, which means signing development and license commercial supply agreements on several product kernels before this year is out. As a reminder, our business targets for 2030 are: three Nanoformed medicines on the market, income growth of more than 50% on average across the 5 years period, and an EBITDA margin above 30% by 2030. With that, I'll hand over to Christian. Please, Christian.

Christian Jones executive
#8

Thanks, Albert. So, as this slide shows, we'll be discussing the encouraging recent feedback we received from the MHRA — that's the regulatory body in the UK. It concerned our nanoenzalutamide product, and there are many different reasons why it's extremely encouraging. The first is the product itself and where it stands on regulatory approval. What it tells us is that we're heading in the right direction. It doesn't guarantee an approval, but it does mean that, scientifically, the FDA feels our rationale for advancing the product is sound, and it's on that basis that we'll be submitting an application to the UK regulatory authorities this year. It also bodes well for other applications we might choose to submit, since other regulators — in Europe certainly, and around the globe — hold the UK authorities in high regard. Beyond that, for our customers in the generic space as well as those in the innovator space, it's very encouraging to see our technology received favorably by regulators. There have been no questions regarding the technology as such. We're delighted with this feedback. Yes, altogether, an extremely encouraging situation. Moving to the next slide, if we look at how we performed in H2, we've had, clearly, that feedback from the MHRA, which I'd describe as pivotal and really quite a milestone.

Christian Jones executive
#9

And then earlier this year we got some very good news regarding the bio deal we signed with a company listed on the US Nasdaq, and that deal centers on our biologics technology. For us as a company, I'd say this has been a genuinely key milestone as we move that biologics technology ahead. It has really helped lift Nanoform's profile in this area for ultra-high-concentration subcutaneous injections. We've seen strong momentum coming out of this, along with further validation of the technology and of the approach of being active in this space and creating value for patients. The third point is that in Q2 we signed 16 new customer projects: three new non-GMP and three GMP projects, which is great. That of course helps keep us on track to deliver more projects this year than we did last year. As I said, momentum around the biologics technology has really sped up, and we currently have multiple major pharma and biotech feasibility projects underway. The key thing, of course, is being able to give all of our partners confidence that our technology isn't just a lab-based approach — we actually have a viable GMP manufacturing process to deliver clinical material, to begin generating value in clinical development and ultimately in commercial manufacturing.

Christian Jones executive
#10

We'll cover more on that in the next couple of slides when Peter speaks, but right now we have advanced negotiations in progress to lock in a strategic GMP partnership for our biologics technology with several different CDMOs. Once we feel the timing is appropriate, we'll make an announcement about it. At this point I'll hand things over to Peter, who will walk us through our product development strategy.

Peter Hänninen executive
#11

Thanks, Christian. My colleagues have already discussed the encouraging MHRA feedback that both we and our partners recently got, and naturally that was exactly what we had been hoping to see too. Without going over all of that again, I would like to point out on my end the common legislative framework that Europe and the UK share here, and that this really demonstrates how different regulators can hold differing views when interpreting these regulatory pathways, yet there is genuinely solid backing for the position we have taken alongside our partners from the very beginning. Importantly, of course, there is a clear route ahead for filing a first marketing application for a Nanoformed medicine during this year. Naturally, we have also kept up disciplined execution across the remainder of the kernel pipeline, particularly the programs that are furthest along. As you can see, we have added a line here too, since we now hold a 9% ownership stake in PluriVitech. That company is a customer we have referenced previously, and it is repurposing an anti-nausea medication for oncology indications, and this new use that PluriVitech is pioneering for that medication calls for a substantially higher dose, so they are seeking an enabling nanoformulation for the product using our particles.

Peter Hänninen executive
#12

Now shifting our focus to biologics — as was noted earlier, right before summer we announced that the first exclusivity agreement for our biologics technology had been signed, and that we're moving forward, or aiming to move forward, into the clinic without delay. We've determined that the quickest and most efficient route here is to work with a CDMO possessing extensive experience in aseptic manufacturing, which our small molecule technology does not call for. Those talks have moved quickly throughout the summer, and naturally we're glad to have now obtained concrete, workable proposals from prospective partners. Our view is that pairing Nanoform's best-in-class particle engineering know-how, on the one hand, with a frontrunner in aseptic biologics production, on the other, will form a competitive proposition for customers weighing clinical trials, and will help speed up commercialization of this technology. This is a slide we've been presenting for a number of quarters now, and the point we wish to emphasize is that an established market and business model exist for drug delivery technologies capable of enabling subcutaneous administration of biologics. The slide really brings out why numerous biologics developers are actively seeking alternatives, given that the business model adopted rests on signing these exclusive deals on a target-by-target basis.

Peter Hänninen executive
#13

In Q2, both the current market leader and our company have been closing deals, and we expect the biologics subcu delivery market to keep expanding from this point—possibly at a faster rate. With that said, I’ll hand it back to Henri.

Operator operator
#14

Should you want to pose a question, press star five on your phone keypad to join the queue. Should you instead decide to pull your question, press star five once more on your phone keypad. Our following question is from Christopher at SEB. You may proceed. Yes,

Christopher Uhde analyst
#15

Hello there. Christopher Uhde here from SEB. I appreciate you taking my questions. What I'm trying to get at, I suppose, is how revenue would be affected by outsourcing the bio process to a CDMO. Suppose, just as an example, we take a 5% royalty as the midpoint of an average royalty, and you're working with a CDMO — how ought we to think about — and I understand this is an ongoing discussion — but how ought we to think about what happens to that royalty level? Thank you.

Henri von Haartman executive
#16

Albert, do you want to handle that one?

Albert Hæggström executive
#17

Yes. In the CDMO space, the business model tends to revolve heavily around fee-for-service, with royalties playing a smaller role. That's more or less the standard when you have mature, readily available technologies. We see things differently. Our approach is closer to that of a proprietary technology provider holding something unique, which lets you create a situation where clients are genuinely willing to pay milestones and royalties for it. We are, of course, in negotiations with several parties right now, and that's an ongoing discussion. To put it this way, it doesn't appear to be a hot topic in the sense that we clearly hold a different strategic and tactical view — they are comfortable focusing on the fee-for-service side, while we can consider the milestones and royalties. I would say that at this point, don't assume there would be any changes to our strategy. That said, of course, this negotiation is still ongoing. That's what I'd like to say.

Christopher Uhde analyst
#18

Possibly I could pose something to clarify. Looking at it through cash flow, can you offer any guidance whatsoever regarding how large the proportional effect might be? Thanks. That's everything from my side.

Albert Hæggström executive
#19

My view is that this would have a clearly positive effect on Nanoform's cash flow and revenue. As for precisely how the split works, think of it this way: we do the nanoforming, they provide other services at their facilities, and naturally the precise share differs. In absolute terms, we expect this to be strongly beneficial for our cash flow and top line. As I mentioned, we stand apart in the sense that our technology is unique, and they acknowledge that.

Christopher Uhde analyst
#20

Thanks a lot.

Operator operator
#21

Our following question is from Christian Glennie at Stifel. Go ahead, please.

Christian Glennie analyst
#22

Hello, and good morning, everyone. Perhaps regarding the UK process specifically, it's clear that you've seen differing results now, first with the EMA and afterward with the UK. What do you see as the reasons behind the acceptance on the UK side compared with the EMA? Might there be any chance this could affect the EMA process in turn, or is that likely too much of a stretch at this stage? Thank you.

Edward Hæggström executive
#23

Thank you. If I could offer some speculation here, I believe the concrete factor that was different between the first interaction we described on the prior call and this one comes down to something known as ICH M15 — a document that already existed at the time of our first interaction but had not yet been ratified, and it has since been ratified. That alone could be one possible explanation. Naturally, each individual authority has, as its prerogative, the ability to interpret the situation as it sees fit. Then there's the last part of your question — whether a feedback loop exists, meaning that if positive outcomes show up in country one, two, three, could that influence other countries with which we have or haven't interacted? Again, this is speculative, but my presumption would be that it is the case. Thanks.

Christian Glennie analyst
#24

Thanks. So where things stand on possible partnerships for the UK market, at least — what's the status of any talks that may be underway, or how much interest has this generated? And when do you see the ideal timing for a commercial deal, given that you're also thinking about regulatory filings? Thank you.

Edward Hæggström executive
#25

I'll begin, and then perhaps Christian can add to that. My view has always been that speed matters, and speaking up sooner is preferable, and any favorable development that emerges genuinely benefits both the discussions already underway and those that are just getting started. Christian might be able to offer a bit more detail.

Christian Jones executive
#26

Yes. Clearly, we are holding discussions with a wide range of businesses across various geographies, and I think once we have more to share on that front, we will, but it goes without saying that our partners will take this very well — not only those who might have an interest in the UK, but in other regions too.

Christian Glennie analyst
#27

Thank you. Perhaps one last question: I realize, of course, that not much time has passed since you signed that biologics agreement with the US biopharma company. Clearly, you're now discussing the possibility of moving faster into CDMO for GMP, but is there anything specific to flag regarding how the development work is progressing on your end, at least, with that asset? Thank you.

Edward Hæggström executive
#28

No, I don’t believe we have anything specific we can share about that right now. From my perspective, it’s obvious the customer cares a great deal about what we’re doing to secure this biologics GMP status, and we’re working to get it as quickly as possible. Getting it benefits everyone.

Christian Glennie analyst
#29

Thanks a lot — that’s great.

Operator operator
#30

Our following questioner is Sami Sarkamies of Danske Bank Markets. The line is yours.

Sami Särkämies analyst
#31

Hi, I have three questions, and we'll take them one at a time. First, on that first exclusivity deal in biologics: have you recorded any revenue from it yet? When do you expect that to happen, and would it land under revenue or under other operating income?

Henri von Haartman executive
#32

Albert, go ahead.

Albert Hæggström executive
#33

Right, we'll recognize it across the 12-month period, which means — since we signed it in May — the P&L effect is quite minor, as I mentioned. The full amount of money came in during Q2, and that's the reason Q2 cash flow looks stronger than EBITDA, for instance. A small portion of it landed in the top line, the revenue line. Okay.

Sami Särkämies analyst
#34

Then second, on the GMP production side for biologicals, you've started those conversations. What's your expectation for how long they'll run, and what kind of initial reaction or feedback have you gotten from the parties you've reached out to?

Edward Hæggström executive
#35

Perhaps I can begin, and then Peter can add some specifics. As for me, it's difficult to predict what lies ahead. I believe that carrying out the negotiations effectively serves everyone's interest, and that also means doing so as quickly as we can. That said, a lot of details have to be settled, so expect this to require a little time. As for how people view this, I think every one of the various parties we've spoken with has received it very positively. That positivity stems from the fact that we aren't pushing a technology here; we're making sure to meet a need that a customer has stated explicitly. Peter, please.

Peter Hänninen executive
#36

Thanks, Edward. There isn’t a great deal for me to add beyond this: it’s all happened across the summer and holiday stretch, and despite that, talks have moved along quite well — to the stage where, as we’ve said, we now have concrete, feasible proposals in hand. We feel optimistic, and we expect that positive momentum to carry on, though naturally we can’t give any guidance on it. Okay.

Sami Särkämies analyst
#37

And then last, on nanoenzalutamide, you'll be submitting in the UK before the year is out, but could you give a rundown of the other steps you have underway for the remaining European markets as well as the US market?

Edward Hæggström executive
#38

Albert, given that we're on a financial call, perhaps you'd like to handle this one. I mention it only because this is the program I devote a great deal of time to — across the originator, the generic, and the technical side. Albert, go ahead.

Albert Hæggström executive
#39

Since we're pursuing a multitrack strategy, as we note in the report, we've already signed agreements and have negotiations that have been underway for quite a long time in a great many markets. Naturally, we're staying in close touch with every party involved. As we've also mentioned, over the next few months, we will — we've now gotten feedback from — first, we received feedback from one European authority, and now we've gotten feedback from the UK, which came back positive following potentially the change in the guidance or the ratification of the guidelines. In the months ahead, before the year is out, we'll have feedback from additional countries, and from the US as well, for example. We'll keep you updated, and this is, of course, something we do jointly with both the commercial partners who've signed and the partners we're still in discussions with. In certain cases, it's the consortium working alongside us that is more in the driver's seat, and in other cases it's the partners on the commercialization side. We'll keep you informed once we have more to share.

Sami Särkämies analyst
#40

Thanks. That’s all from me — no more questions.

Albert Hæggström executive
#41

It's reasonable to say we expect the close of this year to be quite interesting over the next 4, 5 months. We're going to receive a great deal more information.

Operator operator
#42

That brings us to the end of the Q&A. I'll return the call to the speakers for any final remarks.

Henri von Haartman executive
#43

Thanks, operator. For Nanoform, I want to express appreciation to everyone who joined us today, and should you have further questions, please don't hesitate to get in touch with us. We hope each of you has a wonderful Thursday afternoon and evening. Thanks, and farewell.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Nanoform Finland Oyj transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Nanoform Finland Oyj earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.